{
    "2021-07-13": [
        [
            {
                "time": "",
                "original_text": "睿智医药乱象丛生 盈利能力低下 增速远逊同行",
                "features": {
                    "keywords": [
                        "睿智医药",
                        "乱象丛生",
                        "盈利能力低下",
                        "增速远逊同行"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "JP Morgan Chase 增持康龙化成股份约23.67万股",
                "features": {
                    "keywords": [
                        "JP Morgan Chase",
                        "增持",
                        "康龙化成",
                        "23.67万股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "21硬核研报丨CRO淘金赛道“领跌者” 泰格医药转型“投资家”AB面",
                "features": {
                    "keywords": [
                        "CRO",
                        "淘金赛道",
                        "领跌者",
                        "泰格医药",
                        "转型",
                        "投资家"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "2021年医药生物中期策略报告：需求长期景气 布局创新、医疗服务和消费主线",
                "features": {
                    "keywords": [
                        "2021年",
                        "医药生物",
                        "中期策略",
                        "需求长期景气",
                        "布局创新",
                        "医疗服务",
                        "消费主线"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}